Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Teresa L. Knight, MD, FACOG, Chief Medical Officer of the Women’s Health Specialists of Saint Louis, discusses treating lupus in women. To learn more about the Women’s Health…
NEW YORK (Reuters Health) – In pregnant women with objective evidence of abnormal vaginal flora, clindamycin administered before 22 weeks of gestation significantly reduces the rate of late…
NEW YORK (Reuters Health) – Among women undergoing in vitro fertilization, the need for salpingectomy does not reduce subsequent ovarian response to controlled hyperstimulation for oocyte retrieval, a…
NEW YORK (Reuters Health) – The increasingly prevalent birth defect gastroschisis is not related to intake of individual nutrients by mothers, researchers report in a March 11th on-line…
NEW YORK (Reuters Health) – A challenge to broadly implementing human papillomavirus (HPV) vaccination programs in developing countries is delivering all 3 recommended doses of vaccine to adolescents…
NEW YORK (Reuters Health) – In women with metastatic breast cancer, a longer duration of chemotherapy is associated with a clinically meaningful and statistically significant improvement in time…
NEW YORK (Reuters Health) – Results of the Infant Cooling Evaluation (ICE) trial confirm that moderate therapeutic hypothermia reduces death and disability in term and near-term infants who…
NEW YORK (Reuters Health) – Fifteen years after postoperative pelvic radiotherapy for endometrial carcinoma, many women still suffer from urinary and bowel symptoms and have reduced physical functioning,…
NEW YORK (Reuters Health) – A pH-balanced vaginal gel can alleviate vulvovaginal symptoms after treatment for breast cancer, according to results of randomized controlled study published in the…
NEW YORK (Reuters Health) – A low-dose oral contraceptive is effective in relieving primary dysmenorrhea, according to the results of a randomized controlled trial conducted in Japan and…
